Role of MicroRNA-223 and MicroRNA-182 as Novel Biomarkers in Early Detection of Colorectal Cancer

Abstract

Background Colorectal cancer is a common and lethal disease. It is estimated that approximately 145,600 new cases of large bowel cancer are diagnosed annually in the USA. MiRNA-223 and miRNA-182 have been reported in various cancers, such as lung, gastric, breast and colorectal cancer and proposed to be valid and reliable for diagnosis as well as prognosis. Aim This study aimed to determine the role of miR-223 and miR-182 as novel biomarkers for early detection and prognosis of CRC. Patient and Methods This case–control study was conducted at the department of Internal Medicine, Aswan University Hospital, in the period from the 1st of February 2020 to the 20th of April 2021. Thirty-five cases and thirty age- and sex-matched controls were included in the study. All patients were subject to complete clinical evaluation, routine investigations, occult blood in stool, serum levels of CEA and CA 19–9, serum levels of miR-223 and miR-182 by quantitative PCR. Results Significant difference between the two studied groups regarding biomarker changes was found. ROC curve analysis showed that the new markers had excellent diagnostic as well as prognostic criteria. Micro-RNA-223 diagnostic accuracy, sensitivity, specificity, PPV, NPV, FDR and FOR were 97%, 97.1%, 96.7%, 97%, 97%, 3.3% and 2.9%, respectively. Also, micro-RNA-182 diagnostic accuracy, sensitivity, specificity, PPV, NPV, FDR and FOR were 97%, 98%, 96%, 96%, 98%, 3.9% and 2%, respectively. Conclusion MiR-223 and miR-182 have been discovered to be relevant and reliable biomarkers for the early identification and prognosis of CRC. Increased levels of miR-223 and miR-182 were associated with increased risk of disease progression, and the more accurate the value of miR-223 and miR-182, the earlier the diagnosis of colorectal cancer.

MicroRNA‐506 ameliorates breast cancer‐induced osteolytic bone metastasis via the NFATc‐1 signaling pathway

“…Increasing evidence has shown that abnormally expressed miRNAs might be considered as the prognostic markers. [33,34] Our findings confirmed the obvious downregulation of Previous reports revealed that breast cancer could promote RANKL-induced osteoclastogenesis in vitro, [35] we then explored whether miR-506 affected the RANKL-induced osteoclastogenesis.…”

“…Increasing evidence has shown that abnormally expressed miRNAs might be considered as the prognostic markers. [ 33,34 ] Our findings confirmed the obvious downregulation of miR‐506 in breast cancer in tissue samples of breast cancer patients and cell lines, indicating that miR‐506 might be a potential prognostic marker for breast cancer.…”

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice

“…These results suggest that miR-223 could be a potential therapeutic target in patients with CRC [166]. In addition to these data, the quantification of miR-223 levels in plasma could be an accurate and reliable biomarker for the early identification and prognosis of CRC [168,169].…”

Inflammasomes Are Influenced by Epigenetic and Autophagy Mechanisms in Colorectal Cancer Signaling

“…In the transcriptionally active phase, miR-223 has the potential to modulate NLRP3 mRNA [ 64 ], and miR-223 can attach to a highly conserved region of the 3′UTR of NLRP3 mRNA and consequently inhibit protein translation, according to an in silico analysis [ 65 ]. While miR-223 has been associated with decreased NLRP3 expression and IL1β secretion in inflammatory circumstances, there is inconclusive evidence regarding its effects in sporadic CRC [ 66 , 67 , 68 ]. A recent study revealed that wild-type miR-223 may exert a more potent anticancer effect in sporadic CRC when compared with glibenclamid [ 69 ].…”